 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
Dr. Daniel Sigg is an entrepreneurial physician scientist and brings over 20 years of clinical, translational research and business industry experience to the position as CEO of NanoCor. Previous positions of Dr. Sigg include Chief Scientific Officer of LecTec Corporation, a public company focused on transdermal drug delivery & IP licensing, Medical Director at Novo Nordisk and various R&D leadership positions at Medtronic. Daniel has focused his career at Medtronic on the development of novel drug/biologic device combination products. He has been instrumental in the regulatory approval of a novel pacing lead, a drug-device combination product, and the formation and execution of innovative Biotechnology programs at CRDM including leading a major gene therapy program utilizing AAV vector as delivery platform with an external / internal development program. Daniel is a board-certified Anesthesiologist (Switzerland), and also ECFMG certified (US licensing exam for foreign physicians). Daniel holds a position as Adjunct Assistant Professor of the Department of Integrative Biology & Physiology at the U of MN, and publishes and teaches regularly. He is inventor of 5 issued and over 20 pending US patent applications. Daniel holds a MD from the University of Basel, Switzerland, and a PhD degree in Cellular & Integrative Physiology from the University of Minnesota.
Dr. Miller is a world-leading cardiologist, and specifically in the areas of heart failure and transplant. Dr. Miller was previously the Director of the cardiac programs at Georgetown University School of Medicine, Georgetown University Hospital, and Washington Hospital Center. Prior to that, he was professor and director of the cardiovascular division at the University of Minnesota. Dr. Miller has served as an investigator in more than 80 clinical trials, and one of his research foci is the use of ventricular assist devices as a platform for delivery of new therapies including stem cell and gene therapies. He is now the Chairman of the Department of Cardiovascular Medicine at the University of South Florida, and Associate Director of the Regenerative Medicine Program.
Ms. Mikhail has almost 20 years of broad-based experience in management consulting and corporate law. She is a founder of Asklepios BioPharmaceutical, Inc., and in her role as Chief Executive Officer, raised over $8 million, primarily in non-dilutive funding, and took the company’s gene therapy based therapeutic for Duchenne Muscular Dystrophy into human clinical trials. Prior to practicing law, Sheila worked as a consultant for Arthur Andersen in Chicago where she specialized in mergers and acquisitions, cross-border transactions and integration issues. She also worked with A.T. Kearney and the Acumen Group where she advised emerging companies on the commercialization of new technologies and Fortune 100 companies on turn around and operational strategies to improve profitability. She was also Law Clerk to the Honorable Martha Craig Daughtrey, 6th Circuit, US Court of Appeals. Sheila received a B.S. from the University of Illinois at Urbana-Champaign, with highest honors; a finance M.B.A. from the University of Chicago, with honors; and a J.D. from Northwestern University, with honors. Sheila is admitted to the bars of Massachusetts, Arizona, New York and North Carolina. She is a member of the American Bar Association Committees on business law; private equity and venture capital.
Dr. Samulski received his Ph.D. in Medical Microbiology and Immunology from the University of Florida. Dr. Samulski’s graduate work demonstrated the first use of AAV as a viral vector and culminated in the first US patent involving non-AAV genes inserted into AAV. After completing post-doctoral training at Princeton, Dr. Samulski was hired to provide his expertise in AAV biology as a member of the scientific advisory board of Avigen, a new AAV research company. Later, in 1993, Dr. Samulski co-founded an AAV-based gene therapy company called Merlin. This research group was headed by Dr. Xiao and was the first group to demonstrate AAV-mediated long-term gene transduction in muscle. This finding precipitated a merger of Merlin with Somatix, Inc., which then merged in 1995 with Cell Genesys. In total, Dr. Samulski has worked with AAV for 25 years, and for the past 8 years, has been director of the University of North Carolina Gene Therapy Center. Dr. Samulski has over 20 patents filed or issued in the area of AAV vectors. Dr. Samulski is a former member of the Recombinant DNA Advisory Committee (RAC), a committee tasked with assisting the FDA with approving or disapproving gene therapy clinical trials in the United States. He also frequently serves as a gene therapy consultant to the FDA. Through the UNC gene therapy center, Dr. Samulski produced FDA-approved AAV clinical vector used to treat children with the neurological disorder of Canavan’s disease (now a total of 7 children – ages 2 - 6). He has received the first lifetime achievement award at the American Society of Gene Therapy (ASGT).
Dr. Gerald Klein became a director of the Oxygen Biotherapeutics in March 2008. He has served as Vice President of Global Medical and Clinical Affairs and Chief Medical Officer for Talecris Biotherapeutics since September 2005. His responsibilities there include global clinical development and medical affairs. For two years prior to September 2005, he was the Vice President of Medical Affairs and Clinical Research at Dey LP in Napa, California. Dr. Klein earned his medical degree from the University of Brussels Medical School in Belgium, and holds board certifications issued by the American Board of Pediatrics and the American Board of Allergy and Clinical Immunology. Dr. Klein practiced Allergy in San Diego Country while being on the faculty of the University CA, Irvine. He became a professor of Clinical Medicine and Pediatrics, at that institution. While being on the clinical faculty, Dr. Klein published numerous peer reviewed papers, in allergy and asthma. He was also very active in national medical organizations as served on the Board of Regents of the American College of Allergy, Asthma, and Clinical Immunology. While in practice, Dr. Klein founded San Diego Clinical Research Associates, a site management organization that he sold to Research Across America, as well as founding SDCRA, a contract research organization which was sold to Quintiles. He then joined Quintiles, as a Sr. Vice President, of clinical development. Dr. Klein spent four years there working on domestic as well as international clinical trials. After leaving Quintiles, Dr. Klein became an EVP at Clingenics, a combination of a CRO and pharmacogenomics company. During this time Dr. Klein founded Externa Pharmceutical Company, where he served as CEO. Dr. Klein was recruited to Specialty Laboratory, a large commercial and central laboratory, where he served as VP of Clinical Trials. Dr. Klein, together with some former employees from Specialty Labs, and Bay City Capital, founded Pathway Diagnostic and served as its executive vice president. He than moved to Napa, CA to join Dey LP as VP of Medical and Clinical Affairs in October 2003 and served there until September 2005.
Dr. Rubanyi is recently retired as the Vice President and Head of the Gene Therapy Department at Berlex Biosciences in Richmond, California and Adjunct Professor of Molecular and Cellular Physiology at the University of California at Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex., the largest (660+ enrolled patients in 110+ centers world-wide) and most advanced (two pivotal Phase III trials) cardiovascular gene therapy clinical program to date. Formerly, he was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories, Cedar Knolls, New Jersey (1987-1990) and Associate Professor at the Mayo Clinic Medical School, Rochester, Minnesota (1983-1987). The author and co-author of 22 books and over 325 research articles, he serves as an editorial board member for several biomedical journals and is a member of numerous American and international scientific societies. He is the Founder of the biomedical journal Endothelium. His pioneering work on the nature and characterization of endothelium-derived relaxing and contracting factors contributed in a significant way to the present knowledge about endothelial control of vascular function in health and disease.
Dr. Evangelia Kranias, the developer of the I-1 technology, is well known for her work in calcium cycling proteins and the biology of heart failure, and is a Distinguished University Research Professor, Hanna Professor of Cardiology and Chair of the Department of Pharmacology and Cell Biophysics at the University of Cincinnati. She obtained her Ph.D. in Molecular Biology and Biochemistry from Northwestern University in 1974. She was a postdoctoral fellow and Instructor at Northwestern University Medical School from 1974-1977 and subsequently she joined the faculty at the University of Cincinnati College of Medicine in 1978. Dr. Kranias has received many awards and honors and has been a recipient of the prestigious Research Career Development award and a MERIT (10 year funding) award from the National Institutes of Health and the Daniel Drake Medal. More recently, she was named an AHA Distinguished scientist. She has been elected as a Council Member to several societies and as a founding Fellow of the International Society of Heart Research (FISHR) and a fellow of the American Heart association (FAHA) and the American Physiological Society. Dr. Kranias has also served on several editorial boards and she is currently an Associate Editor for Hellenic Journal of Cardiology and a Consulting Editor for Physiology. Her scientific research has been funded by NIH for the past 30 years, often with multiple awards. She has led an internationally recognized program in cardiovascular biology. She is an author on over 280 scientific publications. Over the past 30 years, Dr. Kranias has consistently made important and seminal contributions to molecular cardiology and the understanding of heart disease and heart function under physiological and patho-physiological conditions with specific emphasis in heart failure. The body of her research spans numerous biological systems utilizing integrative approaches. Dr Kranias is one of the leaders in molecular cardiology and her ground-breaking scientific investigation in the arena of heart failure has received world-wide recognition, innumerable invitations to present the work throughout the world, as well as invitations to organize and chair several scientific meetings.
Dr. Roger Hajjar, a cardiologist, and translational scientist, is a leader in gene therapy techniques and model testing for cardiovascular diseases. Dr. Hajjar is Professor of Medicine, Cardiology, and Professor of Gene and Cell Medicine at Mount Sinai Medical Center, New York, as well as Research Director of Mount Sinai's Wiener Family Cardiovascular Research Laboratories. Dr. Hajjar is the director of Cardiovascular Research at Mount Sinai Medical Center. He received his medical degree from Harvard Medical School and trained in internal medicine and cardiology at Massachusetts General Hospital in Boston. Dr Hajjar has significant expertise in gene therapy His laboratory has validated the cardiac sarcoplasmic reticulum calcium ATPase pump, SERCA2a, as a target in heart failure, developed methodologies for cardiac directed gene transfer. He has initiated and recently completed a phase 1 and phase 2 First-in-Man clinical trials of SERCA2a gene transfer in patients with advanced heart failure under his guidance.
|
||||
| NanoCor's Team | ||||
|
|
||||
| Contact Us | ||||
|
||||
870 Martin Luther King Jr. Blvd.
NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a minimal-invasive treatment for these patients and advance the current standard of care.